DNTH vs. INDV, TGTX, ACAD, BHC, ARVN, DCPH, MRVI, RYTM, GERN, and VERA
Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Indivior (INDV), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Arvinas (ARVN), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), Rhythm Pharmaceuticals (RYTM), Geron (GERN), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical preparations" industry.
Dianthus Therapeutics (NASDAQ:DNTH) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability.
47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Dianthus Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
In the previous week, Indivior had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 5 mentions for Indivior and 2 mentions for Dianthus Therapeutics. Indivior's average media sentiment score of 1.39 beat Dianthus Therapeutics' score of 0.94 indicating that Indivior is being referred to more favorably in the news media.
Dianthus Therapeutics received 9 more outperform votes than Indivior when rated by MarketBeat users.
Dianthus Therapeutics currently has a consensus target price of $42.83, suggesting a potential upside of 98.21%. Indivior has a consensus target price of $36.00, suggesting a potential upside of 96.51%. Given Dianthus Therapeutics' higher probable upside, equities analysts clearly believe Dianthus Therapeutics is more favorable than Indivior.
Indivior has a net margin of 0.44% compared to Dianthus Therapeutics' net margin of 0.00%. Indivior's return on equity of 842.72% beat Dianthus Therapeutics' return on equity.
Indivior has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Summary
Indivior beats Dianthus Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Dianthus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dianthus Therapeutics Competitors List
Related Companies and Tools
